Discovery and Development of RSV604

Antiviral Drugs: From Basic Discovery through Clinical Trials

Volumn , Issue , 2011, Pages 367-382

  Chapman, Joanna ^a   Cockerill, Stuart ^a  

^a Arrow Therapeutics Ltd   (United Kingdom)

Author keywords

Activity vs. RSV and pharmacokinetics of leading chiral benzodiazepines; Phase I III safety and efficacy original proof of concept (POC) trial for RSV604; RSV604 discovery and development

Indexed keywords

EID: 84886016802     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470929353.ch26     Document Type: Chapter

References (48)

1. Hall, C. B.; Weinberg, G. A.; Iwane, M. K.; Blumkin, A. K.; Edwards, K. M.; Staat, M. A.; Auinger, P.; Griffin, M. R.; Poehling, K. A.; Erdman, D.; et al. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 2009, 360, 588-598.
2. Iwane, M. K.; Edwards, K. M.; Szilagyi, P. G.; Walker, F. J.; Griffin, M. R.; Weinberg, G. A.; Coulen, C.; Poehling, K. A.; Shone, L. P.; Balter, S.; et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus and parainfluenza viruses among young children. Pediatrics 2004, 113, 1758-1764.
3. Schanzer, D. L.; Langley, J.M.; Tam, T.W. S. Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr. Infect. Dis. J. 2006, 25, 795-800.
4. Nicholson, K. G.; McNally, T.; Silverman, M.; Simons, P.; Stockton, J. D.; Zambon, M. C. Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children. Vaccine 2006, 24, 102-108.
5. Thompson, W. W.; Shay, D. K.; Weintraub, E.; Brammer, L.; Cox, N.;Anderson, L. J.; Fukuda,K.Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289, 179-186.
6. Falsey, A. R.; Hennessey, P. A.; Formica, M. A.; Cox, C.; Walsh, E. E. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 2005, 352, 1749-1759.
7. Ebbert, J. O.; Limper, A. H. Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome. Respiration 2005, 72, 263-269.
8. Hegele, R. G.; Hayashi, S.; Bramley, A. M.; Hogg, J. C. Persistence of respiratory syncytial virus genome and protein after acute bronchiolitis in guinea pigs. Chest 1994, 105, 1848-1852.
9. Valarcher, J. F.; Bourhy, H.; Lavenu, A.; Bourges-Abella, N.; Roth, M.; Andreoletti, O.; Ave, P.; Schelcher, F. Persistent infection of B lymphocytes by bovine respiratory syncytial virus. Virology 2001, 291, 55-67.
10. Hruska, J. F.; Bernstein, J. M.; Douglas, R. G., Jr.; Hall, C. B. Effects of ribavirin on respiratory syncytial virus in vitro. Antimicrob. Agents Chemother. 1980, 17, 770-775.
11. Ventre, K.; Randolph, A.G. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst. Rev. 2004, CD000181.
12. Englund, J. In search of a vaccine for respiratory syncytial virus: the saga continues. J. Infect.Dis. 2005, 191, 1036-1039.
13. Kim, H. W.; Canchola, J. G.; Brandt, B. D.; Pyles, G.; Chanock, R. M.; Jensen, K.; Parrott, R. H. Respiratory syncytial disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 1969, 89, 422-434.
14. Johnson, P. R.; Spriggs, M. K.; Olmsted, R.A.; Collins, P. L. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive divergence between antigenically related proteins. Proc. Natl. Acad. Sci. USA 1987, 84, 5625-5629.
15. Johnson, P. R.; Collins, P. L. The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness. J. Gen. Virol. 1988, 69, 2623-2628.
16. Johnson, P. R.; Collins, P. L. The 1B (NS2), 1C (NS1) and N proteins of human respiratory syncytial virus (RSV) of antigenic subgroups A and B: sequence conservation and divergence within RSV genomic RNA. J. Gen. Virol. 1989, 70, 1539-1547.
17. Cane, P. A.; Matthews, D. A.; Pringle, C. R. Analysis of relatedness of subgroup A respiratory syncytial viruses isolated worldwide. Virus Res. 1992, 25, 15-22.
18. Cane, P. A.; Matthews, D. A.; Pringle, C. R. Analysis of respiratory syncytial virus strain variation in successive epidemics in one city. J. Clin. Microbiol. 1994, 32, 1-4.
19. Peret, T. C.; Hall, C. B.; Schnabel, K. C.; Golub, J. A.; Anderson, L. J. Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J. Gen. Virol. 1998, 79, 2221-2229.
20. Cane, P. A. Molecular epidemiology of respiratory syncytial virus. Rev. Med. Virol. 2001, 11, 103-116.
21. Waris, M. Pattern of respiratory syncytial virus epidemics in Finland: two-year cycles with alternating prevalence of groups A and B. J. Infect. Dis. 1991, 163, 464-469.
22. McKimm-Breschkin, J. L. A simplified plaque assay for respiratory syncytial virus: direct visualisation of plaques without immunostaining. J. Virol. Methods 2004, 120, 113-117.
23. Domachowske, J. B.;Bonville,C.A.; Rosenberg,H. F.Animal models for studying respiratory syncytial virus infection and its long term effects on lung function. Pediatr. Infect. Dis. J. 2004, 23, S228-S234.
24. Sidwell, R. W.; Barnard, D. L. Respiratory syncytial virus infections: recent prospects for control. Antiviral Res. 2006, 71, 379-390.
25. Douglas, J. L.; Panis, M. L.; Ho, E.; Lin, K.-Y.; Krawczyk, S. H.; Grant, D. M.; Cai, R.; Swaminathan, S.; Chen, X.; Cihlar, T. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob. Agents Chemother. 2005, 49, 2460-2466.
26. Nikitenko, A. A.; Raifeld, Y. E.; Wang, T. Z. The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus. Bioorg. Med. Chem. Lett. 2001, 11, 1041-1044.
27. Weiss, W. J.; Murphy, T.; Lynch, M. E.; Frye, J.; Buklan, A.; Gray, B.; Lenoy, E.; Mitelman, S.; O'Connell, J.; Quartuccio, S.; Huntley, C. Inhalation efficacy of RFI-641 in an African green monkey model of RSV infection. J. Med. Primatol. 2003, 32, 82-88.
28. Andries, K.; Moeremans, M.; Geyers, T.; Willebrords, R.; Sommen, C.; Lacrampe, J.; Janssens, F.; Wyde, P. R. Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res. 2003, 60, 209-219.
29. Cianci,C.;Yu,K.-L.;Combrink, K.; Sin,N.; Pearce,B.;Wang, A.; Civiello, R.; Voss, S.; Luo, G.; Kadow, K.; et al. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob. Agents Chemother. 2004, 48, 413-422.
30. Wyde, P. R.; Chetty, S. N.; Timmerman, P.; Gilbert, B. E.; Andries, K. Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Antiviral Res. 2003, 60, 209-219.
31. Bonfanti, J. F.; Doublet, F.; Fortin, J.; Lacrampe, J.; Guillemont, J.; Muller, P.; Queguiner, L.; Arnoult, E.; Gevers, T.; Janssens, P.; et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate: 1. improving the pharmacokinetic profile using the structure-property relationship. J. Med. Chem. 2007, 50, 4572-4584.
32. Bonfanti, J. F.; Meyer, C.; Doublet, F.; Fortin, J.; Muller, P.; Queguiner, L.; Gevers, T.; Janssens, P.; Szel, H.; Willebrords, R.; et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate: 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J. Med. Chem. 2008, 51, 875-896.
33. Ni, L.; Zhao, L.; Qian, Y.; Zhu, J.; Jin, Z.; Chen, Y. W.; Tien, P.; Gao, G. F. Design and characterization of human respiratory syncytial virus entry inhibitors. Antiviral Ther. 2005, 10, 833-840.
34. Sudo, K.; Miyazaki, Y.; Kojima, N.; Kobayashi, M.; Suzuki, H.; Shintani, M.; Shimizu, Y. YM-53403, a unique antirespiratory syncytial virus agent with a novel mechanism of action. Antiviral Res. 2005, 65, 125-131.
35. Alvarez, R.; Elbashir, S.; Borland, T.; Toudjarska, I.; Hadwiger, P.; John, M.; Roehl, I.; Shulga Morskyaya, S.; Martinello, R.; Kahn, J.; et al. RNAi-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob. Agents Chemother. 2009, Jun 8. EPub.
36. Carter, M. C.; Alber, D. G.; Baxter, R. C.; Bithell, S. K.; Budworth, J.; Chubb, A.; Cockerill, G. S.; Dowdell, V. C. L.; Henderson, E. A.; Keegan, S. J.; et al. 1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. J. Med. Chem. 2006, 49, 2311-2319.
37. Henderson, E. A.; Alber, D. G.; Baxter, R. C.; Bithell, S. K.; Budworth, J.; Carter, M. C.; Chubb, A.; Cockerill, G. S.; Dowdell, V. C. L.; Fraser, I. J.; et al. 1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. the identification of a clinical candidate. J. Med. Chem. 2007, 50, 1685-1692.
38. Chapman, J.; Abbott, E.; Alber, D. G.; Baxter, R. C.; Bithell, S. K.; Henderson, E. A.; Carter, M. C.; Chambers, P.; Chubb, A.; Cockerill, G. S.; et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob. Agents Chemother. 2007, 51, 3346-3353.
39. Collins, P. L.; Chanock, R. M.;Murphy, B. R. Respiratory syncytial virus. In Fields Virology, 4th ed., Knipe, D. M., Howley, P. M., Griffin, D. E., Lamb, R. A.,Martin,M. A., Roizman, B., Straus, S. E., Eds.; Lippincott Williams & Wilkins, Philadelphia, 2001, pp. 1443-1485.
40. Omari, K. E.; Scott, K.; Dhaliwal, B.; Ren, J.; Abrescia, N. G. A.; Budworth, J.; Lockyer, M.; Powell, K. L.; Hawkins, A. R.; Stammers, D. K. Crystallization and preliminary x-ray analysis of the human respiratory syncytial virus nucleocapsid protein. Acta Crystallogr. 2008, 64, 1019-1023.
41. Zhang, L.; Peeples, M. E.; Boucher, R. C.; Collins, P. L.; Pickles, R. J. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells and without obvious cytopathology. J. Virol. 2002, 76, 5654-5666.
42. Sherrill, R. G.; Sugg, E. E. An improved synthesis and resolution of 3-amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones. J. Org. Chem. 1995, 60, 730-734.
43. Reider, P. J.; Davis, P.; Hughes, D. L.; Grabowski, E. J. J. J. Org. Chem. 1987, 52, 957-958.
44. Bock, M. G.; DiPardo, R. M.; Evans, B. E.; Rittle, K. E.; Veber, D. F.; Freidinger, R. M.; Hirshfield, J.; Springer, J. P. J. Org. Chem. 1987, 52, 3232-3239.
45. Gershwin, L. J.; Schelegle, E. S.; Gunther, R. A.; Anderson, M. L.; Woolums, A. R.; Larochelle, D. R.; Boyle, G. A.; Friebertshauser, K. E.; Singer, R. S. A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology. Vaccine 1998, 16, 1225-1236.
46. CEREP screen. See http://www.cerep.fr for details of screen and protocols.
47. Dent, J.; Grieve, S.; Harland, R.; Alber, D.; Sanderson, B.; Lonsdale, F.; Thomson, E.; Smith, G.; Allan, G.; Powell, K. Multiple-dose safety and pharmacokinetics of A-60444, a novel compound active against respiratory syncytial virus (RSV). Poster F-483. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, Dec. 16-19, 2005.
48. Marty, F. A double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of RSV604 in adults with respiratory syncytial virus infection following stem cell transplantation. IXth International Symposium on Respiratory Viral Infections, Causeway Bay, Hong Kong, Mar. 3-6, 2007.